AZN vs MLSS

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

MLSS exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from chronic unprofitability with a profit margin of -63.77% and an ROE of -132.38%, while revenue growth has stagnated at a negligible 2.20% YoY. Despite a low debt-to-equity ratio, the poor quick ratio (0.44) and consistent earnings misses over 25 quarters suggest a failing business model. The stock is technically bearish with a 5-year price decline of 87.7%, making it a high-risk speculative asset with no fundamental floor.